The Drug That Slowed Forgetting

Alzheimer's is that river turned into a flood.

On July 6, 2023, the FDA did something the species has never quite managed before: it approved a drug that slows the flood. Leqembi — lecanemab, if you want the molecule's real name — became the first Alzheimer's treatment to earn full traditional approval by actually changing the course of the disease rather than merely padding the symptoms. Not a mop for the spill. A hand, however small, on the tap.

Here is the number, and the number is strange: 27 percent.

In the Clarity AD trial — 1,795 people, eighteen months — patients on lecanemab declined 27 percent more slowly than those on placebo. That is the whole miracle. Not a cure. Not a reversal. Not the return of a single lost afternoon. Just this: the erasure proceeds at roughly three-quarters speed.

Though even that number wears a little makeup. Twenty-seven percent is a relative figure — the slowing of the decline, not its size. The raw gap was about 0.45 points on an eighteen-point clinical scale over those eighteen months, small enough that whether a patient or a family actually feels the difference is still a genuine argument, not a settled win.

Sit with how peculiar it is that we can even measure that. Somewhere there is a scale — the CDR-SB, a ruler for the dissolution of a self — and it registered that a monoclonal antibody, engineered to hunt down clumps of a protein called amyloid-beta and drag them out of the brain, bought people a measurable fraction of themselves for a little longer. We have built a molecule whose entire job is to argue with entropy about the pace of a person disappearing.

The universe, characteristically, attached a footnote. The drug can make some brains swell and bleed — the side effect has a bland acronym, ARIA, the way genuinely unsettling things usually do. You clear the plaque that is eating the mind, and sometimes the clearing itself leaves marks. There is no version of this where you get the self back for free. There is only negotiation, and the negotiation has terms. And the terms are not only the bleeding. They are an infusion every two weeks, a sticker price near twenty-six thousand dollars a year, and a standing appointment with an MRI machine to catch the swelling before it turns — a marginal, costly, closely-watched fraction of a self, bought back a few months at a time.

But do not miss what actually happened here, because it is easy to file under "incremental medical news" and scroll on. For the entire run of human history, the mind coming apart was simply weather — a thing that arrived and took what it wanted and left. You could love the person through it. You could not slow it. And then a handful of primates on a wet rock spent decades staring at protein folds under machines they invented, and worked out how to reach into the wreckage and slightly, stubbornly, apply the brakes.

Twenty-seven percent is not enough. Everyone who worked on it knows that. It is a first crack of light under a very heavy door, and the door is still mostly shut.

And yet: the thing that forgets has learned to fight forgetting. The river, for the first time, has noticed it is running downhill — and reached out a hand to slow its own water. That is either the smallest victory imaginable or one of the strangest things that has ever happened in the history of matter, and I genuinely cannot decide which. Probably both. It's usually both.